Physician profile
Christopher R Collaco
NPI 1982622510
$21,353.88
in general payments reported to CMS, 2019-2025
34 companies · $10K in 2025
The $10K reported for 2025 was more than what 88% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,228 · 2020: $808 · 2021: $1,855 · 2022: $2,766 · 2023: $1,777 · 2024: $1,917 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,200 · Food and Beverage: $6,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,200.00 |
| Food and Beverage | $6,496.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $7,864.45 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals Lp | $2,124.91 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Genzyme Corporation | $1,558.01 | 2019-2025 | |
| Optinose US, INC. | $1,458.52 | 2019-2024 | |
| Glaxosmithkline, LLC. | $1,302.56 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Incyte Corporation | $686.72 | 2021-2025 | Opzelura |
| Grifols USA, LLC | $686.47 | 2021-2025 | Xembify |
| Pfizer INC. | $562.90 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $455.22 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $427.50 | 2019-2022 | |
| Genentech USA, INC. | $423.13 | 2019-2025 | Xolair |
| Galderma Laboratories, L.P. | $401.96 | 2025 | Nemluvio |
| Blueprint Medicines Corporation | $377.75 | 2023-2025 | Ayvakit |
| Abbvie INC. | $352.16 | 2023-2024 | Rinvoq |
| Alk-Abello, INC | $291.15 | 2019-2023 | Grastek, Odactra |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $267.09 | 2022-2025 | Xolair |
| Biocryst US Sales Co., LLC | $249.40 | 2021-2023 | Orladeyo |
| Organon LLC | $244.63 | 2025 | Vtama |
| Teva Pharmaceuticals USA, INC. | $239.59 | 2021-2022 | |
| Pharming Healthcare, INC. | $236.75 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $197.73 | 2021-2024 | Takhzyro |
| Adma Biomanufacturing LLC | $170.83 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.14 | 2020-2021 | |
| Shire North American Group INC | $108.29 | 2019 | |
| Cycle Pharmaceuticals INC | $95.44 | 2025 | Sajazir |
| Ethicon US, LLC | $83.36 | 2022 | |
| Amgen INC. | $70.61 | 2022-2024 | Tezspire |
| Sanofi-Aventis U.S. LLC | $66.67 | 2019 | |
| Intersect Ent, INC. | $65.32 | 2019 | |
| Kaleo, INC. | $37.28 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $24.87 | 2025 | Alvesco |
| Hikma Pharmaceuticals USA | $24.61 | 2022 | |
| Eyevance Pharmaceuticals LLC | $21.95 | 2020 | |
| Covis Pharma Gmbh | $20.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Collaco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.